• If you are wondering whether BioMarin Pharmaceutical's current share price reflects its true value, a useful starting point is understanding how the market has treated the stock recently.
• BioMarin's share price closed at US$54.12, with returns of 0.4% over 7 days, a 3.7% decline over 30 days, a 9.0% decline year to date, and a 9.5% decline over the last year, alongside longer term 43.3% and 28.3% declines over 3 and 5 years.
• These returns suggest many investors are likely reassessing whether the current price still lines up with the company's long term prospects or whether sentiment has simply shifted away from the stock. In that context, it is especially important to focus on what the underlying valuation frameworks are indicating right now.
• BioMarin currently has a valuation score of 2 out of 6. The rest of this article will walk through the main valuation approaches that sit behind that figure, then finish with a broader way to think about what "fair value" really means for this stock.

BioMarin Pharmaceutical scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: BioMarin Pharmaceutical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash it might generate in the future and then discounting those cash flows back to today using a required rate of return.

For BioMarin Pharmaceutical, the model used is a 2 Stage Free Cash Flow to Equity approach built on cash flow projections. The latest twelve month Free Cash Flow is about $761.2 million. Analyst and extrapolated estimates point to projected Free Cash Flow of about $1.59 billion by 2030, with interim projections between 2026 and 2035 ranging from $972 million to about $2.01 billion, all expressed in dollars.

When all those projected cash flows are discounted back and added up, the resulting estimated intrinsic value is $193.36 per share. Against the recent share price of $54.12, the model output indicates the stock is 72.0% undervalued based on these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioMarin Pharmaceutical is undervalued by 72.0%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: BioMarin Pharmaceutical Price vs Earnings

For a profitable company, the P/E ratio is a useful check on how much you are paying for each dollar of earnings. It links the share price directly to the bottom line, which is usually what ultimately matters for long term shareholders.

What counts as a normal or fair P/E depends on how quickly earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually point to a lower one.

BioMarin Pharmaceutical currently trades on a P/E of 38.92x. That sits above the Biotechs industry average P/E of 17.75x and the broader peer average of 18.65x. Simply Wall St’s Fair Ratio for the stock is 23.20x, which is its view of the P/E you might expect given factors such as earnings growth profile, profit margins, market cap, industry and specific risks.

The Fair Ratio is more tailored than a simple comparison with peers or the industry because it adjusts for company specific characteristics instead of assuming all biotechs should trade on the same multiple. Comparing 38.92x with the 23.20x Fair Ratio suggests the stock is trading above this fair value estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your BioMarin Pharmaceutical Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about BioMarin Pharmaceutical to the numbers by linking a clear view of the business, a forecast for revenue, earnings and margins, and an assumed fair value. All of this is available in an accessible tool on the Community page that updates when new news or earnings arrive. It also helps you compare that fair value to the current price so you can judge whether the stock fits your own view. For example, one investor might build a cautious BioMarin narrative around a Fair Value near US$55.36 that focuses on VOXZOGO and pricing risks, while another might choose a more optimistic narrative closer to US$120 that focuses on rare disease portfolio expansion and the potential impact of acquisitions.

Do you think there's more to the story for BioMarin Pharmaceutical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.